KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) FCF Margin: 2009-2025

Historic FCF Margin for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to 43.84%.

  • Biomarin Pharmaceutical's FCF Margin rose 1661.00% to 43.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.89%, marking a year-over-year increase of 1527.00%. This contributed to the annual value of 17.08% for FY2024, which is 1449.00% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its FCF Margin stood at 43.84% for Q3 2025, which was up 115.16% from 20.37% recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's FCF Margin peaked at 43.84% during Q3 2025, and registered a low of -16.50% during Q1 2023.
  • Its 3-year average for FCF Margin is 14.79%, with a median of 19.59% in 2023.
  • In the last 5 years, Biomarin Pharmaceutical's FCF Margin soared by 2,921bps in 2021 and then tumbled by 3,240bps in 2022.
  • Biomarin Pharmaceutical's FCF Margin (Quarterly) stood at -3.90% in 2021, then slumped by 147bps to -5.38% in 2022, then skyrocketed by 515bps to -0.22% in 2023, then spiked by 2,245bps to 22.23% in 2024, then surged by 1,661bps to 43.84% in 2025.
  • Its FCF Margin was 43.84% in Q3 2025, compared to 20.37% in Q2 2025 and 21.15% in Q1 2025.